DONATE TODAY
To Increase Patient Access
SHOW POST CATEGORIESSHOW ALL POSTS

Post Category: Awareness

September 6, 2023
More Great News For The Fight Against GBM!

Northwest Biotherapeutics has applied for approval to market DCVax®, a personalized immune therapy, for the treatment of Glioblastoma.

Read More
August 14, 2023
Ask for Gleolan Before Brain Tumor Resection

Gleolan is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Read More
December 3, 2022
"20 Years of Increasing Patient ACCESS” to Specialists, Advanced Treatment Options, INCLUDING Treatments that are Standard of Care or FDA Approved that Patients are NOT Offered, Diagnostics and Clinical Trials

The End Brain Cancer Initiative (EBCI) and I are once again thrilled to have this platform to increase patient education, awareness & outreach to the global brain tumor community and to the general public with the goal of increasing their direct access to top brain tumor specialists at brain tumor centers of excellence, multiple treatment options/diagnostics and clinical trials.

Read More
August 1, 2022
DISEASE EDUCATION: The End Brain Cancer Initiative (EBCI) this month is sharing with you information related to a very rare disease that only affects @ 1,500 people in the U.S. annually. This disease is known as PCNSL

PROSPECT is an open-label, Phase II study evaluating the efficacy, safety, and pharmacokinetics of an investigational oral medicine called Tirabrutinib (ONO-4059), for patients with primary central nervous system lymphoma (PCNSL).

Read More
July 20, 2022
July 20th is National GBM Awareness Day

Your support is essential to ensuring that the unmet needs of the brain tumor community continue to be heard and addressed. Together, we can advocate for patients and families today, while fueling research with the potential to become the treatments and cures of tomorrow.

Read More
May 7, 2022
ADVANCED MRI APPLICATIONS FOR RECURRENT GLIOBLASTOMA BRAIN TUMORS & A NEW PHASE 1 CLINICAL TRIAL

Imaging Biometrics (IB) has been developing imaging analysis software for primary brain tumors for close to 30 years. Recently, their imaging software was used to assess treatment response in a pre-clinical study of Gallium Maltolate.

Read More
February 8, 2022
“Incisionless Surgery” Treatment Approach:
Metabolic Targeting of GBM

This month’s CURE MAG Cover Tip brought to you by the End Brain Cancer Initiative (EBCI) and through our patient advocacy and disease education partnership with CURE, focuses on turning Glioblastoma Multiforme (GBM) from a deadly disease into a chronic managed disease.

Read More
February 2, 2022
DEMAND YOUR SURGEON TO VISUALIZE BRAIN CANCER IN A DIFFERENT LIGHT

This month’s Advocacy & Disease Education Cover Tip is shedding a light on a neuro-surgical FDA-approved imaging agent known as Gleolan Brain Dye/Aminolevulinic Acid HCI. The benefit of Gleolan is that it helps neurosurgeons to see “high grade gliomas”.

Read More
September 10, 2021
The Importance of Shared Decision-Making for Patients With Glioblastoma

Navigating care for patients with cancer can be overwhelming considering the multiple specialists they encounter and the numerous decisions they must make. For patients with GBM management is further complicated by a poor prognosis, feelings of isolation, urgency to treat, and cognitive decline.

Read More
July 21, 2021
GBM Awareness Day 2021

Join us in honoring brain cancer patients, families, friends, and caregivers. Support efforts to develop better treatments.

Read More
June 24, 2021
ASCO Annual Meeting Wrap Up

As a proud member of ASCO (American Society of Clinical Oncology), I am consistently impressed with the information they provide. They recently held their Annual Event I wanted to take the time to provide some of the incredible information and data that resulted from that meeting.

Read More
December 19, 2020
KIYATEC – A potential game-changer in informing your brain tumor treatment decision

Groundbreaking news in the battle against brain cancer.It’s a response-prediction test which improves outcomes by testing live cancer cells against a number of potential therapies to demonstrate which ones will be most effective in killing the tumor cells.

Read More
1 2 3 4

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram